# Article information:

Biology | Free Full-Text | Ranacyclin-NF, a Novel Bowman–Birk Type Protease Inhibitor from the Skin Secretion of the East Asian Frog, Pelophylax nigromaculatus  
<https://www.mdpi.com/2079-7737/9/7/149>

# Article summary:

1. A novel Bowman–Birk type inhibitor, named ranacyclin-NF (RNF), was identified in the skin secretion of the East Asian frog, Pelophylax nigromaculatus.

2. RNF displayed trypsin inhibitory activity with an inhibitory constant, Ki, of 447 nM and had negligible direct cytotoxicity.

3. Two analogues of RNF were designed based on some features of ORB and ranacyclin-T to study structure–activity relationships.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

This article is a reliable source of information about the discovery of a novel Bowman–Birk type inhibitor from the skin secretion of the East Asian frog, Pelophylax nigromaculatus. The authors provide detailed information about the peptide’s properties and its potential therapeutic applications. The article is well-written and provides clear explanations for each point made. The authors also provide evidence to support their claims, such as data from functional assays and structure–activity studies.

The article does not appear to be biased or one-sided in its reporting; it presents both sides equally and does not make any unsupported claims or omit any points of consideration that could affect the reliability of its conclusions. Furthermore, there are no promotional elements present in the article that could influence readers’ opinions or lead them to draw false conclusions about the peptide’s potential therapeutic applications.

The only potential issue with this article is that it does not explore any counterarguments or possible risks associated with using this peptide as a therapeutic agent. It would have been beneficial if these points had been discussed in more detail so that readers can make an informed decision about whether or not they should pursue further research into this peptide’s potential therapeutic applications.

# Topics for further research:

* Potential risks of using Bowman–Birk type inhibitors
* Adverse effects of Pelophylax nigromaculatus peptide
* Therapeutic applications of Bowman–Birk type inhibitors
* Structure–activity studies of Pelophylax nigromaculatus peptide
* Clinical trials of Bowman–Birk type inhibitors
* Regulatory considerations for Bowman–Birk type inhibitors

# Report location:

<https://www.fullpicture.app/item/2bfb45191ce1117740ed49f0b7eb8ece>